Research & Development: Page 73
-
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology POOL Dr. Diane JORKASKY Aileron Therapeutics Appoints Medical Chief Aileron Therapeutics, a biotechnology company discovering and developing a novel class of therapeutics called stapled peptides, has appointed Diane Jorkasky, M.D., senior VP, head of development and chief medical of...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
E-media
E-upgrades and enhancements Prolifiq’s recent software release, Prolifiq for Life Sciences, is designed to help pharma, biotech, and medical-device companies comply with an increasingly complex web of regulations governing electronic sales communications. Constantly evolving guidelines, regulatio...
By PharmaVoice Team • Dec. 28, 2009 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
What's New
Oncology Performance Edge, Health Strategies Group’s recently launched strategic research service, helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources. “The oncology market is significantly different from others,...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Most Americans Want More Info on New Biotechnologies Sidebars: What Do You Think Synthetic Biology Is? Rating the Best Drivers of Attendance to speaker events Pharma Rebranding of Speaker Events Is Paying Off Japan Prese...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
The Year Ahead
Looking back to the varying changes and pressures the industry has endured, and ahead to how the industry will need to reinvent itself to continue to prosper, companies are adapting to longer-term marketplace trends and evolving patient needs. The industry is facing pressure from the economic, re...
By Denise Myshko and Robin Robinson • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
The Safety First Era
The classwide requirement for Risk Evaluation and Mitigation Strategies (REMS) for opioid products is likely to have a profound impact on the pharmaceutical industry and healthcare. While most REMS involve only a medication guide — which is likely to have little impact on the prescribing process ...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
RNAI Technology
Coming of Age: RNAi Technology As advances in genetics continue to improve our understanding of disease, RNAi will have the opportunity to create entirely new classes of medicines. Researchers say RNA-based therapeutic technology will have a tremendous impact on pharmaceutical research in the n...
By Denise Myshko • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
Supply Chain Strategies
Companies need to evaluate their business through their value streams rather than by individual processes or components. ccording to Bob Silvers, managing director, at SSA & Co., by applying the rigors of Lean Six Sigma to underperforming areas, pharmaceutical companies can completely transfo...
By Denise Myshko • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
The Executive Suite
Meeting challenges head-on David E. I. Pyott, CBE Chairman of the Board and CEO Allergan Inc. Allergan draws stability, strength, and value from its growth equation — a business model that balances diverse specialties with a focused approach and a leadership presence in markets around the globe. ...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
On the Calendar
November 16-17 Pharmaceutical Coverage & Reimbursement Conference Washington, D.C. Q1 Productions, q1productions.com November 16-17 The 3rd Pediatric Clinical Trials Grand Hyatt Washington, Washington, D.C. ExL Pharma, exlpharma.com November 17-18, 2009 13th Advanced Forum on Structuring, Neg...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
Index
Julian Adams, Ph.D. President, Research and Development and Chief Scientific Officer, Infinity Pharmaceuticals Inc. Brent Ahrens. General Partner, Canaan Partners Kenneth C. Aldrich. CEO, Chairman, and Co-Founder, International Stem Cell Corp. Meryl Allison. Principal, Deloitte Consulting Karl...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Service Consolidation Recommended for Clinical trial Offices Emerging centralized clinical trial offices (CTOs) are among the newest developments within the research administration infrastructure of academic health centers. Little uniformity exists in the structure or functions of existing CTOs, ...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
What's New
inVentiv Health’s recently launched risk evaluation and mitigation strategy (REMS) offering provides pharmaceutical and biotechnology clients with a customizable suite of REMS-related services that can be delivered through a single, integrated program. In an effort to assure safe use of prescript...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
buster brands,”says David Lipson,forecasting practice leader at IMS Global Consulting.“But we are not see ing the avalanche that some feared. Although the number of major new product launches was smaller than usual last year, the genuine value provided by medicines introduced over the past dozen ...
By PharmaVoice Team • Nov. 3, 2009 -
PharmaVoice Team/PharmaVoice
The End of the Paper Chase
Responses to an ongoing survey and face to face discussions with executives from pharmaceutical and biotech companies reveal their greatest concerns and hopes as they begin to streamline the clinicaltrials process. IN AN EXCLUSIVE WITH PHARMAVOICE, ELLEN SEMPLE,VP, MARKETING, CB TECHNOLOGIES INC....
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Robert GELBARD ICN Pharmaceuticals Appoints Former Ambassador to Head International Efforts Former Ambassador Robert Gelbard joins ICN Pharmaceuticals Inc. as senior VP for international affairs and government relations. Mr. Gelbard is the com pany representative with foreign governme...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES BioSpace Inc., a provider of Webbased products and information services to the life sciences industry, has formed a collaboration with MediBic, a Japanese bioventure company, to exchange information in an effort to support new biot...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
What's New
WHAT’S NEW NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Noonan Russo Communications has agreed to merge its operations with the public relations division of Euro RSCG Healthview, establishing a new company — Noonan Russo Presence Euro RSCG. The new entity, a differentiated communicatio...
By PharmaVoice Team • Oct. 30, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Extending its line of therapeutic class research, NOP World Health has added Diabetes Patient Market Study to its portfolio of disease state research. The staff of diabetes experts who support the study, which has been produced by NOP World Health’s sister com pany, RoperASW since 1989, will be i...
By PharmaVoice Team • Oct. 30, 2009 -
PharmaVoice Team/PharmaVoice
Pharma Outlet
The pharmaceutical industry is facing a crucial short age in the area of clinical trials. With an estimated 4,360 new drugs in the pipeline, it has become an increasing challenge for the industry to recruit both qualified patient volunteers and experienced researchers. Only an estimated 5 million...
By Kathleen H. Drennan • Oct. 29, 2009 -
PharmaVoice Team/PharmaVoice
Brave New Digital World
Pharma companies must be bold and confident in their deployment of electronic solutions or risk being left behind on the technological superhighway. Patients and physicians are migrating in droves toward Web- and mobile-based healthcare solutions. The overall number of e-health consumers who go o...
By PharmaVoice Team • Oct. 27, 2009 -
PharmaVoice Team/PharmaVoice
What's Missing in eSolutions: Enabling the Redefinition of Clinical Development
There’s something missing from the eSolutions discussion. In fact, there are two key missing links: n eSolutions that are no more than bridges between silos will not meet the needs of a rapidly changing clinical development environment; and n Strategies, pilots, and initial use of eSolutions are ...
By PharmaVoice Team • Oct. 27, 2009 -
PharmaVoice Team/PharmaVoice
eClinical Feedback: Why Sponsors Need an Integrated, Closed-Loop Clinical Process
David Gemzik, Vice President, Implementation Services Sean Cheng, Senior Product Marketing Manager Faced with slowing pipe lines and spiraling costs in new drug development, sponsors in recent years have been trying to conquer the last frontier in process improvement: R&D. However, increasing...
By PharmaVoice Team • Oct. 27, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
3 PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Virginia Kirk Denise Myshko Elisabeth Pena Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, ...
By Taren Grom • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
The Nose Knows
Many of the properties that make the nose an effective way for an illicit drug user to get a “fix” are actually qualities that doctors and patients are seeking for legitimate treatments — a noninjection form that delivers medication in highly targeted, quickly absorbed doses. Britannia Pharmaceut...
By Taren Grom • Oct. 23, 2009
Previous
